Ann: SIRFLOX Awarded Oral Presentation at ASCO, page-34

Sirtex is pleased that the preliminary analysis showed that SIR-Spheres Y-90 resin microspheres did result in a statistically significant improvement in Progression-Free Survival (PFS) in the liver.

Mr Gilman Wong, CEO of Sirtex commented “We are honoured the Scientific Program Committee has selected the SIRFLOX study for the Oral Abstract Session, which will allow the critical review of the study data as part of the overall peer review and validation process at the ASCO Annual Meeting, in front of such a large clinical audience.”

Would be surprised for Sirtex to announce they were "pleased" if the results for liver-specific PFS were a dud. Looks like the SP has found a base, perhaps the sell off reflects nerves from the big drop in March. Based upon the run-up in early April I think there is good upside potential from here IMHO, but please DYOR.